AFP and hepatocellular carcinoma: Most importantly, some of the potential glycopeptide biomarkers described above exceeded the AUC of AFP (79%) and thus also improved the clinical value of AFP, as the commonly accepted HCC biomarker for the same cohort (Supplementary Figure 2).